Selecta Biosciences (NASDAQ:RNAC) is a biotechnology company focused on harnessing its proprietary immune tolerance platform, ImmTOR, aiming to mitigate unwanted immune responses. Their mission is to develop highly targeted therapies for rare and serious diseases. Operating at the cutting edge of immunology, Selecta Biosciences is leading the charge in creating novel treatments that enhance the efficacy and safety of biologics, gene therapies, and vaccines. Among its key projects, the company is advancing a pipeline of candidates addressing diseases such as chronic refractory gout, methylmalonic acidemia, and more. By pioneering the development of immune-modulating drugs, Selecta Biosciences seeks to bring life-changing treatments to patients with unmet medical needs, marking significant advancements in the realm of therapeutic biotechnology.